New Partnership Between Onboard Dynamics and T.D. Williamson Aims to Reduce Pipeline Emissions Across Eastern Hemisphere
5.6.2025 07:00:00 CEST | Business Wire | Press Release
Onboard Dynamics LLC (“Onboard Dynamics”), a leading developer of pipeline evacuation technology, has entered into a strategic partnership with T.D. Williamson (“TDW”), a global provider of pipeline services and equipment. This collaboration will enable TDW to represent, market, and sell Onboard Dynamics’ products and services directly to customers across the Eastern Hemisphere through its own network of channel partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604551886/en/
Onboard Dynamics’ GoVAC® Pipeline Evacuation System—an innovative, self-powered mobile unit designed to capture and recover natural gas during pipeline evacuations, eliminating the need for venting or flaring. Pictured here in action during a pipeline drawdown project in France.
The partnership spans a broad and strategically important region—including Europe, Central Asia, the Middle East, Africa, India, and the Asia-Pacific—where the demand for sustainable pipeline solutions is rapidly growing. Together, the companies aim to support regional efforts to reduce carbon emissions by minimizing methane releases during pipeline evacuation operations.
“This partnership with Onboard Dynamics brings cutting-edge pipeline evacuation technology to our customers outside of North America,” said Laurent Fabry, Sr Director Sales Operations Europe Caspian & Africa at T.D. Williamson. “It enhances our ability to support clients in reducing emissions during natural gas pipeline maintenance, aligning with our shared commitment to environmental stewardship and service excellence.”
Mitch Schmidtke, CEO of Onboard Dynamics, added: “The importance of this strategic partnership with TDW cannot be overstated. It validates the strength of our technology and significantly accelerates our global reach. Together, we are equipping the natural gas pipeline industry in the Eastern Hemisphere with the tools needed to meet both operational and environmental goals.”
By combining TDW’s renowned quality service and technical expertise with Onboard Dynamics’ emissions-reducing technology, the partnership delivers comprehensive pipeline integrity and emissions management solutions.
About Onboard Dynamics LLC
Founded in 2013, the goal of Onboard Dynamics is to support the natural gas ecosystem in reducing global greenhouse gas (GHG) emissions safely and reliably through innovative and practical commercial solutions. Our compression-based systems minimize methane and other GHG releases during pipeline operations and maintenance. Learn more at: www.onboarddynamics.com.
About T.D. Williamson
T.D. Williamson (TDW) draws upon more than 100 years of industry expertise and experience to help operators of pressurized pipeline systems keep the world's energy lifelines running safely and reliably. TDW delivers an unmatched, patented portfolio of technology, products and services for the life of a pipeline including pigging, hot tapping and isolation, integrity assessment and repair to support operators in protecting the environment and moving toward a more sustainable energy future. Find out more at www.tdwilliamson.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604551886/en/
Contacts
Media Contact:
Jason Vosburgh
Director of Marketing
Onboard Dynamics
Jason.vosburgh@onboarddynamics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom